AN ANALYSIS OF THE GROWTH AND PERFORMANCE OF THE INDIAN PHARMACEUTICAL SECTOR

Abstract

India’s pharmaceutical industry acts as a crucial global healthcare engine, contributing 2% to the national GDP and 6% to total merchandise shipments with FY 2023-24 exports hitting USD 27.9 billion. Driven by a 10-12% CAGR across over 3,000 companies and 10,500 manufacturing plants, the sector is on track to nearly double from a USD 65 billion valuations in 2024 to USD 120-130 billion by 2030. Strategic state interventions including a ₹15,000 crore PLI for finished formulations and a combined ₹9,940 crore bulk drug investment helped total pharmaceutical turnover reach a record ₹4,71,898 crore in FY 2024-25, reducing dollar-denominated drug imports by 36.13% (from USD 7,515 million to USD 4,800 million) and pushing the net trade surplus to an absolute peak of USD 26,700 million. However, this growth highlights a stark dual-speed imbalance against the domestic medical devices (Meditech) sector, which remains highly import-dependent and burdened by a five-year trade deficit of ₹22,639 crore, capped by an import surge of USD 8,822 million. To secure long-term market leadership and structural resilience, India must aggressively eliminate manufacturing bottlenecks by establishing specialized clusters for high-import items like Electro-Medical Equipment (which drains over USD 5,000 million in imports annually) and expanding export channels beyond its 31% trade reliance on the United States. Furthermore, leveraging the historic mid-year FY 2025–26 healthcare investment inflow of ₹13,193 crore (combining a ₹10,948 crore pharma macro-rebound and ₹2,245 crore in med-tech) will allow the industry to pivot from low-margin generics into high-value biopharmaceuticals, implement sustainable green practices, and escalate R&D funding for original drug discovery.